Enfusion chief accounting officer sells $2,514 in stock

Valeria Gutowski, the Chief Accounting Officer of Enfusion , Inc. (NYSE:ENFN), a $1.47 billion market cap company trading near its 52-week high after a remarkable 41% gain over the past six months, recently sold shares of the company’s Class A common stock. According to InvestingPro analysis, the stock is currently trading close to its Fair Value. According to a recent SEC filing, Gutowski disposed of 219 shares on March 3 at an average price of $11.481 per share, amounting to a total transaction value of $2,514. This sale was made to cover tax withholding obligations related to the issuance of shares, as noted in the filing. Following the transaction, Gutowski retains ownership of 49,397 shares of Enfusion stock. InvestingPro data shows the company maintains strong financial health with a current ratio of 3.42, indicating robust liquidity. For deeper insights into insider trading patterns and 12+ additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Enfusion Inc. announced its fourth-quarter earnings for 2024, coinciding with the company’s acquisition agreement with Clearwater Analytics at $11.25 per share. This acquisition price has become a focal point for analysts and investors. Stifel analysts maintained a Hold rating on Enfusion, aligning their price target with the acquisition offer. Meanwhile, Morgan Stanley (NYSE:MS) downgraded Enfusion from Overweight to Equal-weight, also adjusting their price target to $11.25, reflecting the acquisition terms.

The acquisition agreement, which values Enfusion at a 13% premium over its previous closing price, is seen as favorable by Stifel analysts, who believe a higher competing bid is unlikely. Morgan Stanley’s analysis suggests that the acquisition addresses concerns about Enfusion’s limited public float and its dependency on the startup hedge fund sector. The valuation of the acquisition is based on an estimated 18x multiple on the revised EBITDA forecast, which Morgan Stanley notes is a discount compared to industry peers.

The acquisition represents a significant transition for Enfusion, with both Stifel and Morgan Stanley aligning their price targets with the agreed share price. Investors are closely monitoring these developments as the acquisition process continues. The market’s response reflects the anticipated completion of the deal, with analysts indicating that the stock is expected to stabilize around the acquisition price.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.